{"id":22308,"date":"2025-06-03T04:30:00","date_gmt":"2025-06-03T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-publie-un-amendement-a-son-document-denregistrement-universel-2024\/"},"modified":"2025-06-03T04:30:00","modified_gmt":"2025-06-03T08:30:00","slug":"dbv-technologies-publie-un-amendement-a-son-document-denregistrement-universel-2024","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-publie-un-amendement-a-son-document-denregistrement-universel-2024\/","title":{"rendered":"DBV Technologies publie un amendement \u00e0 son Document d\u2019enregistrement universel 2024"},"content":{"rendered":"<div class=\"pr-date-globe\">June 03, 2025 16:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 3 juin 2025 <\/p>\n<p align=\"justify\"><strong>DBV Technologies publie un amendement \u00e0 son Document d\u2019enregistrement universel 2024<\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext&nbsp;: DBV \u2013 ISIN&nbsp;: FR0010417345 \u2013 Nasdaq Stock Market&nbsp;: DBVT), &lpar;la \u00ab <strong>Soci\u00e9t\u00e9<\/strong> \u00bb), soci\u00e9t\u00e9 biopharmaceutique en phase clinique, annonce le d\u00e9p\u00f4t aupr\u00e8s de l\u2019Autorit\u00e9 des march\u00e9s financiers &lpar;\u00ab&nbsp;<strong>AMF<\/strong>&nbsp;\u00bb) et la mise \u00e0 disposition aupr\u00e8s du public d\u2019un amendement \u00e0 son Document d\u2019enregistrement universel 2024 &lpar;\u00ab&nbsp;l\u2019<strong>Amendement<\/strong>&nbsp;\u00bb). <\/p>\n<p align=\"justify\">Cet Amendement int\u00e8gre notamment une mise \u00e0 jour du Rapport du Conseil d\u2019administration sur le gouvernement d\u2019entreprise afin de tenir compte de la r\u00e9mun\u00e9ration exceptionnelle attribu\u00e9e au Directeur G\u00e9n\u00e9ral par le Conseil d\u2019administration r\u00e9uni le 30 avril 2025. Le versement de cette r\u00e9mun\u00e9ration exceptionnelle reste conditionn\u00e9 \u00e0 son approbation par l\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte, qui se tiendra le mercredi 11 juin 2025.<\/p>\n<p align=\"justify\">Le Document d\u2019enregistrement universel et cet Amendement sont accessibles sur le site internet de la Soci\u00e9t\u00e9 \u00e0 l\u2019adresse&nbsp;: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eVk-PxwIO096ve_hps7i0Y4rfrnJ9zuJ_7oVw6r0XHkCHKAsrYM2-KDNNc9cCbX6kSwXeo1EkHVnzl8GQq7JHAR25OLsMGK4hpcybA1OnblRl-i5p-GvNBx_MCMj-zwx\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/dbv-technologies.com<\/a> et sur le site internet de l\u2019AMF&nbsp;: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eVk-PxwIO096ve_hps7i0aNOcUoLH0BLONqYbcmFqXPZeNaQ1ROy8BccDnb8I80X5S5hPEBsEc5MxDIxXRYh0oW4XTj51-74pt2kyGs-iU0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/amf-france.org\/fr<\/a>. Ils sont \u00e9galement disponibles au si\u00e8ge social de la Soci\u00e9t\u00e9 : 107, avenue de la R\u00e9publique, 92320 Ch\u00e2tillon.<\/p>\n<p align=\"left\"><strong>\u00c0 propos de DBV&nbsp;Technologies<\/strong><\/p>\n<p align=\"justify\">DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa technologie exclusive, le patch VIASKIN\u00ae, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT\u2122), le patch VIASKIN<sup>\u00ae<\/sup> est con\u00e7u pour dispenser des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l\u2019allergie sous-jacente d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec le patch VIASKIN<sup>\u00ae<\/sup> Peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide. <\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;chacun repr\u00e9sentant 5 actions ordinaires) sont n\u00e9goci\u00e9s sur le Nasdaq Stock Market &lpar;symbole : DBVT \u2013 CUSIP : 23306J309). <br \/>Pour plus d\u2019informations, veuillez consulter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jlvyRI0p6qKv-X7ceGMPaKKwH40rG4tjw8PJn1W2zRapzLv_kRZTnvPzV_7ZeTmZxESr9buFoAQW2DvMidI29apojo3JkJu5x9ihzuX9-sc7Il5uR7R3uuoUo15BqwyK\" rel=\"nofollow\" target=\"_blank\" title=\"www.dbv-technologies.com\">www.dbv-technologies.com<\/a> et nous contacter sur <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TIfJV9rPHF2n58WgSiB7OEVARi29sC0TvDt58z6G9pcJQtU4gxvLbiWAk7zqb-Sq8nnLilEWKRoRNQxH_D-NGmi3LwpBqetjxjuiBFtpinvMvwNVoCUw0DQ5UzzKVva5865e94jnzxTdq6YAbEei0J1xS5QQSYVPxD8xZdF4cYabHHhzEEORNBNYew7hwaAl7tRYexLctcbdtvFqGeLyH8e7_Kd3Z9nprjB6csiyZhqFouD63jUq60Pi5Eed0itgAwwEcUE9o0BkNf6ebdBqx6L8GR9PVgQqsmjF0j3dZrktsPA7Ydtx14H2qzszcLOFE3IRLwqMZvUA3Pi8pxvhrPA0bZvz15XcpNEY-PYksXEjsULhap4XSXU4YHFZRyXn78uB9EUt4n0eONidcKfb2g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>X &lpar;anciennement Twitter)<\/u><\/a> et <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rh6URDLx97KWO4EQQI_9A9hCPiqxlAKVFl5IiqvvRkY1yWQ-QeJTFmCxvwpeV_CDfmZi8tQSUc7jhGJqO9JFm1uxPuOUF7jpAYOPf1HLBHi2ZbH4sx1OTp2A4Szjt6hNHfVzlkY5Nlxu49J8bfYlmdTlsg4myZraM1oH5TN3t865ESOy5yEmClX8BRhBnSYrOOBRfcjQpUs2R49kFx5Q3LRy2kuRdn4D8FTQHNOe-shRDnSMTosp-L8gds9u8IKXYN4o73Bp2zjpim6uy2pvf9DdfJQpOp66tr5R200bCVfXsF3gxiD_eXQvtRuhg13ZZZkbBOKHZDnrqyB6-GJ5F0hBiuTiZdNQ2H-pdB7tbZHY6819uT_b_LUEVMhbMvy9TGqS8mqNIW18GzaT9t0whg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>. <\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mJbTAfNDT8jzO-K8HtzRAWlxVUhi53mFPVARaqrEpC9a6gRCfJ3IbfnkQsZ7kMmW_4gGzmAOPqqOlWg-OqLev5n89zRtSZyRaFFmFh_O1m5jA10WeSBMKX61gd9uw4urckDp2IpYVybXdhYH406KKw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>katie.matthews@dbv-technologies.com<\/u><\/a> <\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yzZhHGHGKyF2zFo7JwhPIgMf6GIgehOFEY-rsNMnfUj1j0qfxTQT-abkxjWp71BRUoXmtByTq-8-T4Jrl50Tw2d6C-Ai-WWX2JuAIjkM9zB5RX_EMH5BpFIqC1Lfpj8dQvrtPWSt-AUw8oFwWBQibg==\" rel=\"nofollow\" target=\"_blank\" title=\"angela.marcucci@dbv-technologies.com\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=zgLJxrF5mbFG_d_cPo1_zuQLX8MCkjI6H0VbmNddvF8rsAg24qN_ZkYHS8QNZmzIJ1jygFdz6ZP7Lwhp-uOaU_oTswoib4rFlNwNP7tcZjBLRnW7A83gFmiI8TU6fjX0-p-8Zb-QyicQVvcoklzFoGV7RaGkVPlSH7GUlAd0eGM=\" title=\"version PDF\" rel=\"nofollow\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZjE5OTNjYWQtYTQ3ZC00NjA1LWFkNmQtNDg5YWFmNjE5ODdiLTEwMTExNTItMjAyNS0wNi0wMy1mcg==\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-22308","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22308\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=22308"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=22308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}